Skip to content

Neurocrine Biosciences

US · NBIX #1162 by market cap Listed 1970
150.57 -6.02 -3.84%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 3 in the most recent period (2026/Q4).
  • Total institutional ownership fell 0.9 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
102.30% -0.89pp
Institutions
972 -3
As of
2026/Q4 vs. prior period

Holder types

Mutual Fund78.92%
Hedge Fund13.49%
Public Company3.46%
Government Pension Fund2.64%
Private Company1.64%
Individual/Insider1.20%
Sovereign Wealth Fund1.07%
Insurance Company0.33%
VC/PE Fund0.22%
Endowment Fund0.17%
Family Office/Trust0.18%

Top holders as of 2026-09-30

BlackRock 14.68% · 14.86M sh
Dodge & Cox 5.44% · 5.50M sh
Vanguard Capital Management, LLC 5.17% · 5.24M sh
Vanguard Portfolio Management, LLC 5.00% · 5.06M sh
J.P. Morgan Asset Management, Inc. 4.90% · 4.96M sh
State Street Global Advisors 4.75% · 4.81M sh
AQR Capital Management 2.99% · 3.03M sh
Vestal Point Capital, LP 2.47% · 2.50M sh
Renaissance Technologies Corp. 2.27% · 2.30M sh
Two Sigma Investments, LP 2.05% · 2.08M sh
Geode Capital Management, LLC 2.10% · 2.13M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 16 buys · 30 sells

NameRoleStake
Kevin Gorman Director 0.51%
Kyle Gano Chief Executive Officer 0.15%
Gary Lyons Independent Director 0.12%
Eric Benevich Chief Commercial Officer 0.07%
Darin Lippoldt Chief Legal Officer 0.06%
Eiry Roberts Chief Medical Officer 0.05%
William Rastetter Independent Chairperson 0.04%
Matthew Abernethy Chief Financial Officer 0.04%
Richard Pops Independent Director 0.04%
Julie Cooke Chief Human Resources Officer 0.02%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-09 Sanjay Keswani Former Chief Medical Officer Intent to Sell (Form 144) -53,614 $167.37
2026-11-03 Eiry Roberts Chief Medical Officer Other Derivative Acquisition +1,506 --
2026-11-03 Eiry Roberts Chief Medical Officer Other Derivative Acquisition +8,314 $166.05
2026-11-02 George Morrow Independent Director Derivative Exercise and Sale -15,000 $53.64–168.53
2026-10-31 Kyle Gano Chief Executive Officer Derivative Exercise and Sale -332 $146.10
2026-10-31 Kyle Gano Chief Executive Officer Derivative Exercise and Retained +282 --
2026-09-27 Eiry Roberts Chief Medical Officer Initial Statement of Beneficial 0 --
2026-09-13 Matthew Abernethy Chief Financial Officer Automatic Disposition -2,311 $157.20
2026-09-13 David Boyer Chief Corporate Affairs Officer Automatic Disposition -826 $157.45
2026-09-10 Kevin Gorman Director Sale to Issuer -7,839 $156.22
2026-09-10 Kevin Gorman Director Other Acquisition +14,343 --
2026-09-10 Julie Cooke Chief Human Resources Officer Sale to Issuer -1,936 $156.22
2026-09-10 Julie Cooke Chief Human Resources Officer Other Acquisition +3,587 --
2026-09-10 Eric Benevich Chief Commercial Officer Sale to Issuer -3,386 $156.22
2026-09-10 Eric Benevich Chief Commercial Officer Other Acquisition +6,275 --
2026-09-10 Jude Onyia Chief Scientific Officer Sale to Issuer -1,936 $156.22
2026-09-10 Jude Onyia Chief Scientific Officer Other Acquisition +3,587 --
2026-09-10 Darin Lippoldt Chief Legal Officer Sale to Issuer -2,419 $156.22
2026-09-10 Darin Lippoldt Chief Legal Officer Other Acquisition +4,483 --
2026-09-10 Kyle Gano Chief Executive Officer Sale to Issuer -4,380 $156.22

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.

Neurocrine Biosciences discussion 0 comments

Add a comment